BWS Financial Initiates Coverage of Twist Bioscience with Sell Rating
Fintel reports that on September 9, 2026, BWS Financial initiated coverage of Twist Bioscience (NASDAQGS:TWST) with a Sell recommendation. This initiation was part of a same-day cluster of analyst actions on September 9, 2026, which also included UBS initiating coverage on the company with a Neutral rating.
Prior to this rating action, Twist Bioscience closed at $128.06 on September 8, 2026, and subsequently closed at $125.52 on September 9, 2026. Looking at recent market performance, the stock experienced a price change of -4.18% over one week, relative to a baseline close of $131.00 on September 2, 2026. Over a one-month period, the stock recorded a price change of +8.52% compared to a baseline close of $115.67 on August 7, 2026.
As of August 28, 2026, the current consensus target mean for the stock was $115.26, with a median target of $117.30. This mean target represents an implied change of -8.17%. The prior consensus target mean was $96.22 as of August 4, 2026, representing a consensus target revision of +19.79%.
The broader analyst sentiment, as of the current recommendation period on September 1, 2026, showed a total of 16 recommendations, consisting of 7 strong buy, 7 buy, 2 hold, 0 sell, and 0 strong sell ratings. This breakdown represents 87.5% positive, 12.5% hold, and 0.0% negative recommendations. In comparison, the prior recommendation period on August 1, 2026, also recorded 16 total recommendations, consisting of 7 strong buy, 8 buy, 1 hold, 0 sell, and 0 strong sell ratings, representing 93.8% positive, 6.3% hold, and 0.0% negative recommendations.
Twist Bioscience reported its latest quarterly earnings on August 3, 2026, posting an actual EPS of -0.56 against an estimated EPS of -0.5036. The actual revenue for the quarter was $118,376,000,000,000.00, compared to the estimated revenue of $116,779,463,000,000.00.
According to a Form 8-K filed with the SEC on August 5, 2026, the company announced that on August 4, 2026, it priced an upsized $300.0 million offering. The filing included an Underwriting Agreement dated August 4, 2026, between Twist Bioscience Corporation and Goldman Sachs & Co. LLC, William Blair & Company, L.L.C., Leerink Partners LLC, and Guggenheim Securities, LLC.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 9, 2026 | BWS Financial | Sell | initiated coverage | |
| September 9, 2026 | UBS | Neutral | initiated coverage |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.